AU2011293648B2 - Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy - Google Patents

Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy Download PDF

Info

Publication number
AU2011293648B2
AU2011293648B2 AU2011293648A AU2011293648A AU2011293648B2 AU 2011293648 B2 AU2011293648 B2 AU 2011293648B2 AU 2011293648 A AU2011293648 A AU 2011293648A AU 2011293648 A AU2011293648 A AU 2011293648A AU 2011293648 B2 AU2011293648 B2 AU 2011293648B2
Authority
AU
Australia
Prior art keywords
heart failure
warfarin
pharmaceutically acceptable
human
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011293648A
Other languages
English (en)
Other versions
AU2011293648A1 (en
Inventor
Diego Albrecht
Priyamvada Chandra
Sven Godtfredsen
Pierre Jordaan
Martin Lefkowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44543868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2011293648(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2011293648A1 publication Critical patent/AU2011293648A1/en
Application granted granted Critical
Publication of AU2011293648B2 publication Critical patent/AU2011293648B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011293648A 2010-08-24 2011-08-22 Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy Active AU2011293648B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37641710P 2010-08-24 2010-08-24
US61/376,417 2010-08-24
PCT/US2011/048542 WO2012027237A1 (en) 2010-08-24 2011-08-22 Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy

Publications (2)

Publication Number Publication Date
AU2011293648A1 AU2011293648A1 (en) 2013-03-21
AU2011293648B2 true AU2011293648B2 (en) 2015-02-12

Family

ID=44543868

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011293648A Active AU2011293648B2 (en) 2010-08-24 2011-08-22 Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy

Country Status (17)

Country Link
US (2) US20130158088A1 (ru)
EP (1) EP2608784B1 (ru)
JP (1) JP2013536230A (ru)
KR (1) KR101864865B1 (ru)
CN (1) CN103079554A (ru)
AU (1) AU2011293648B2 (ru)
BR (1) BR112013004192A2 (ru)
CA (1) CA2807830C (ru)
CL (1) CL2013000513A1 (ru)
ES (1) ES2702529T3 (ru)
GT (1) GT201300047A (ru)
MA (1) MA34483B1 (ru)
MX (1) MX341174B (ru)
RU (1) RU2564941C2 (ru)
SG (1) SG187755A1 (ru)
TW (1) TW201208678A (ru)
WO (1) WO2012027237A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2667643C2 (ru) 2012-08-24 2018-09-21 Новартис Аг Ингибиторы nep для лечения заболеваний, характеризующихся увеличением или ремоделированием предсердия
ES2767084T3 (es) * 2013-08-26 2020-06-16 Novartis Ag Nuevo uso
JP2016530282A (ja) * 2013-08-26 2016-09-29 ノバルティス アーゲー 新規使用
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
EP3229799B1 (en) * 2014-12-08 2018-10-17 Crystal Pharmatech Co., Ltd. Crystalline forms of trisodium supramolecular complex comprising valsartan and ahu-377 and methods thereof
AU2017215530B2 (en) 2016-02-03 2019-09-12 Novartis Ag Galenic formulations of organic compounds
US20190307107A1 (en) * 2016-06-13 2019-10-10 The Board Of Regents Of The University Of Texas System Compositions and methods for modeling heart failure with preserved ejection fraction
WO2020039386A1 (en) 2018-08-23 2020-02-27 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
KR102215623B1 (ko) * 2020-07-24 2021-02-15 유니셀랩 주식회사 사쿠비트릴 칼슘염 및 사쿠비트릴 유리염기와 발사르탄을 공동분자로 사용한 새로운 신규 공결정 형태

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056546A1 (en) * 2005-11-09 2007-05-18 Novartis Ag Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0443983T3 (da) 1990-02-19 1996-03-18 Ciba Geigy Ag Acrylforbindelser
US5217996A (en) 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
US6869357B2 (en) * 2001-12-19 2005-03-22 Igt Methods of conducting games of chance and gaming devices with multiple pay lines
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US7857515B2 (en) * 2007-06-15 2010-12-28 S.C. Johnson Home Storage, Inc. Airtight closure mechanism for a reclosable pouch
PT3067043T (pt) 2007-11-06 2023-03-01 Novartis Ag Composições farmacêuticas baseadas em superestruturas de antagonista/bloqueador de receptores da angiotensina (arb) e inibidores da endopeptidase neutra (nep)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056546A1 (en) * 2005-11-09 2007-05-18 Novartis Ag Pharmaceutical combinations of an angiotensin receptor antagonist and an nep inhibitor

Also Published As

Publication number Publication date
MX2013002212A (es) 2013-05-09
CA2807830A1 (en) 2012-03-01
CL2013000513A1 (es) 2014-08-29
BR112013004192A2 (pt) 2016-05-10
KR20130095754A (ko) 2013-08-28
JP2013536230A (ja) 2013-09-19
MA34483B1 (fr) 2013-08-01
MX341174B (es) 2016-08-10
ES2702529T3 (es) 2019-03-01
GT201300047A (es) 2014-07-08
WO2012027237A1 (en) 2012-03-01
TW201208678A (en) 2012-03-01
EP2608784B1 (en) 2018-09-19
SG187755A1 (en) 2013-03-28
US20140329872A1 (en) 2014-11-06
US20130158088A1 (en) 2013-06-20
EP2608784A1 (en) 2013-07-03
AU2011293648A1 (en) 2013-03-21
RU2564941C2 (ru) 2015-10-10
KR101864865B1 (ko) 2018-06-05
RU2013112859A (ru) 2014-09-27
CA2807830C (en) 2018-04-03
CN103079554A (zh) 2013-05-01

Similar Documents

Publication Publication Date Title
AU2011293648B2 (en) Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
AU2008239659B2 (en) Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
US20180161314A1 (en) Methods for Treating Hyperuricemia and Related Diseases
JP2008505126A (ja) 血小板凝集薬を用いる併用療法
CZ300687B6 (cs) Léciva s obsahem ramiprilu k ošetrování kardiovaskulárních príhod
JPH03161444A (ja) 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤
EP2498731A2 (en) Methods of treating or preventing stent thrombosis
CA2733149A1 (en) Use of dronedarone for the preparation of a medicament for the prevention of stroke or transient ischemic attack
JP6151854B2 (ja) 心血管疾患の治療用経口製剤
WO2010136823A1 (en) Angina treatment
JP6840197B2 (ja) 虚血性事象を処置し、その発生率を低減させ、かつ／または予防する方法
JP2016504994A (ja) 糖尿病患者における心血管リスクの治療
JP2001261562A (ja) フィブリノジェネシス抑制剤
CA2861688A1 (en) Methods for treating hyperuricemia and related diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)